Picture a clinical research coordinator at a neurology site running apitegromab. It is October 2025. Her site qualified months ago, IP accountability logs are clean, subjects are enrolled and dosing on schedule. Then the sponsor call comes: the FDA has issued a Complete Response Letter. The reason has nothing to do with efficacy data, nothing to do with her site’s documentation, nothing to do with the patients sitting in her waiting room. A contract manufacturing organization the sponsor selected, hundreds of miles from any trial site, failed a sterile manufacturing inspection. Her study is, functionally, on hold.

That is the operational reality sitting underneath Scholar Rock’s March 31, 2026 BLA resubmission for apitegromab, its spinal muscular atrophy candidate. The company dropped Novo Nordisk’s Catalent Indiana facility as a contract manufacturer entirely, refiling after the FDA classified a recent inspection of that Bloomington, Indiana plant as “Official Action Indicated.” That classification, OAI, means the FDA found an unacceptable state of compliance requiring regulatory action. Scholar Rock’s original BLA had received a Complete Response Letter in September 2025 specifically because of observations at Catalent Indiana. The fix was not a CAPA or a corrective manufacturing protocol. The fix was: find a different plant and start the regulatory clock over.

What “Official Action Indicated” Costs at the Site Level

Sponsors hear OAI as a regulatory problem. Sites live it as an operational one. When a CMO inspection ends in OAI classification and a Warning Letter, the consequence is not just a regulatory delay on the sponsor’s timeline. It is a supply chain interruption that hits every active site simultaneously, with zero warning and no standardized playbook for how to manage the resulting freeze.

The FDA’s November 20, 2025 Warning Letter to Catalent Indiana, LLC cited cGMP deficiencies at the Bloomington sterile fill-finish facility. That facility had been acquired by Novo Nordisk in December 2024, making it part of an ownership transition mid-supply chain. For any sponsor whose IP was manufactured or planned for manufacture at that site, the OAI classification triggered an immediate question: can we release product from this facility while it is under regulatory action? In most cases, the conservative answer is no. Which means enrolled subjects who need their next dose are waiting, site pharmacies are holding inventory they cannot dispense with confidence, and coordinators are fielding calls from patients and families who do not understand why their SMA treatment schedule has gone uncertain.

The operational toll compounds fast. Sites running rare disease protocols like SMA carry some of the most fragile enrolled populations in clinical research. These are not oncology patients accustomed to treatment interruptions as part of disease management. For children and adults with SMA, dosing continuity is the entire point. Any enrollment hold or supply disruption puts retention at serious risk, and in a small-N rare disease trial, losing two or three subjects to withdrawal is not a footnote. It is a statistical problem. Across our network, sites running rare neurological studies cite subject withdrawal following dosing interruptions as one of the three leading causes of enrollment shortfalls, alongside screen failures and investigator availability.

Then there is the amendment cascade. When a sponsor swaps a contract manufacturer, the FDA’s guidance on manufacturing site change supplements requires a Prior Approval Supplement for biological products. That submission must be approved before the new site’s product can be used in a BLA. But the site-level consequences run parallel: every active site using that IND must receive a protocol amendment or administrative notification documenting the manufacturing change, the pharmacy must update its accountability and release procedures, IRBs require notification (and many will require a full amendment review, adding four to six weeks to site restart timelines), and the informed consent form may require update if the manufacturing site or supply chain is described anywhere in the consent language.

The Hidden Budget Line Nobody Accounted For

None of this appears in the clinical operations budget that was approved when the study started.

Manufacturing site changes are a sponsor-level regulatory action, but the operational work lands at the site and CRO level. Coordinators spend hours updating pharmacy binders, processing IRB amendment submissions, re-consenting enrolled subjects if the ICF required update, and answering patient inquiries during the supply gap. CRAs execute additional monitoring visits or remote record reviews to verify the amendment was implemented correctly at every site. CTMs rebuild enrollment timelines from scratch because the hold period has disrupted the dosing windows for subjects mid-titration. None of these are billable line items in the original contract. They fall into the category of “sponsor-directed activities” that sites absorb because the alternative is losing the study entirely.

The European Pharmaceutical Review confirmed that the Bloomington facility, carrying FEI number 3005949964, affected multiple clients beyond Scholar Rock. Every sponsor whose product ran through that fill-finish operation during the inspection window faced the same question about lot release. The operational blast radius of a single OAI classification at a major CMO is not limited to one program. Sites running multiple studies from the same organization can find themselves processing parallel amendment submissions, managing simultaneous hold communications, and triaging which study’s patients need active outreach first.

The per-site cost of a manufacturing-triggered amendment cycle, when you add coordinator hours, IRB fees, CRA monitoring time, and subject re-consent visits, runs between $8,000 and $15,000 at a mid-size site. Across a twenty-site rare disease study, that is a quarter-million dollars in unbudgeted operational work, and it never appears in the headline about the BLA resubmission.

What Operators Need to Do Differently

For site operations leads and CTMs: the moment a sponsor communicates a manufacturing hold or CMO inspection action, open your IRB notification SOP and start the clock. Do not wait for sponsor confirmation that an amendment is required. Pull the current ICF and search it for any language referencing manufacturing, supply chain, or product origin. Check your pharmacy procedures for lot release authorization and confirm what documentation the site needs before dispensing product from a new facility. If your site has a central IRB, contact the IRB coordinator to understand their turnaround expectation for administrative versus substantive amendment review. Getting ahead of that queue by forty-eight hours can save three weeks.

For sponsors and CTMs building operational risk frameworks: the Scholar Rock situation is a case study in why CMO qualification and inspection history must be a standing agenda item in clinical operations governance, not a one-time due diligence step at study startup. ICH E6(R3) Section 5 places responsibility on sponsors for vendor oversight across the trial lifecycle. That obligation does not end at contract signing. A sponsor that monitors CMO inspection databases quarterly, and flags any Form 483 issuance at an active manufacturing site before it escalates to OAI, buys itself weeks of operational preparation time. Scholar Rock’s September 2025 CRL was preceded by the inspection findings. The operational window between inspection and OAI classification is exactly the time to brief sites, prepare amendment templates, and map the IRB submission sequence.

Apitegromab’s March 31, 2026 resubmission represents Scholar Rock’s bet that a clean manufacturing story, built on a different facility, gets the drug to patients this year. Whether the FDA agrees will be clear soon enough. But the sites that kept their SMA patients enrolled through the interruption, updated their binders, re-consented their subjects, and restarted dosing on a new supply chain, did that work without a line item that covered it.

The next OAI classification at a major fill-finish CMO is not a hypothetical. The FDA’s inspection cadence makes it a scheduling question. The sites and sponsors that build amendment-ready infrastructure before the call comes will lose weeks. The ones that do not will lose months.

References

  1. FierceBiotech — “Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug”
  2. Xtalks — “FDA Flags cGMP Deficiencies at Former Catalent Site Now Owned by Novo Nordisk”
  3. MarketBeat — Scholar Rock (SRRK) FDA Events: BLA Resubmission March 31, 2026
  4. European Pharmaceutical Review — “Novo Nordisk manufacturing facility and clients hit by FDA action”
  5. FDA — “Manufacturing Site Change Supplements: Content and Submission; Guidance for Industry and FDA Staff”
+ posts